Divi's Labs: Strong Q3, growth outlook positive, valuation debate continues

Q: How long will it take to read this news story?

The story "Divi&#039;s Labs: Strong Q3, growth outlook positive, valuation debate continues" has 660 words across 22 sentences, which will take approximately 3 - 6 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Divi&#039;s Labs: Strong Q3, growth outlook positive, valuation debate continues" was covered 8 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 280 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #25874289</li><li>URL: https://chronographically.beamstart.com/news/divis-labs-strong-q3-growth-17386421936102</li></ul>

Business Standard Logo Business Standard 8h ago

Divi's Labs: Strong Q3, growth outlook positive, valuation debate continues - Business Standard

Quick Summary:

Divi's Laboratories share price surged 5.36 per cent at Rs 6,205 per share on the BSE in the intraday trade of Tuesday.

Earnings before interest, tax, depreciation and amortisation (Ebitda) rose to Rs 743 crore from Rs 500 crore, with margins improving to 32.04 per cent from 26.9 per cent Y-o-Y.

Jefferies retained a “Hold” at Rs 6,280, noting strong custom synthesis growth and a better product mix but flagged pricing pressure in generics and the need to diversify beyond Sacubitril Valsartan by FY27, according to reports.